ELDRED KARY

Director Eldred Kary purchases 300 shares of GALT at $2.70; stock down 58.2% from 52-week high amid unprofitable operations.

Eldred Kary, a Director at Galectin Therapeutics, purchased 300 shares at $2.70 on 2026-02-06, increasing his holdings to 65.7K shares. The purchase occurred as GALT trades at -58.2% from its 52-week high of $6.51 and has declined 50.6% over the past 90 days. Notably, Kary's prior trades at GALT show mixed timing results: two recent buys in late December 2025 are down 5.4% in the 30-day window, while earlier 2025 and 2024 purchases demonstrated stronger outcomes (70.6% and 101.2% 90-day gains respectively). The company remains unprofitable with a net loss of $8.2M in its most recent fiscal year, creating fundamental headwinds that complicate interpretation of director buying activity as a confidence signal.

Director Eldred Kary purchases 700 GALT shares at $3.73; stock down 25.4% in 30 days amid -$8.2M net income.

Eldred Kary, a director, purchased 700 shares of Galectin Therapeutics at $3.73 on 2025-12-23, increasing his holdings to 65.4K shares. The timing occurs within a steep drawdown: the stock has declined 25.4% over 30 days and 16.0% over 90 days, trading 38.7% below its 52-week high of $6.51. Notably, his prior four completed GALT trades show a 3-of-4 success rate at the 90-day mark (three generated positive returns of +33.3%, +50.0%, and +63.6%, while one underperformed at -52.7%), establishing a pattern of opportunistic entry timing at this ticker. However, the company remains unprofitable, with a full-year net income of -$8.2M, which frames this purchase as occurring during fundamental stress rather than near a business inflection point.

GALT director Eldred Kary buys 700 shares at $3.73 on 12/23; stock down 38.7% YTD, but prior GALT buys showed +70.6% and +101.2% 90-day returns.

Eldred Kary purchased 700 shares of GALECTIN THERAPEUTICS INC at $3.73, adding 1.1% to his 64.7K share position at a time when the stock trades at $3.99, down 25.4% over the prior 30 days and 38.7% from its 52-week high of $6.51. The company reported net income of $-8,200,000.00 in its most recent fiscal year. However, Kary's prior transaction history at GALT shows a consistent pattern of well-timed entry points: his four prior measurable buys at this ticker yielded +33.3%, +50.0%, +6.9%, and -26.8% returns at 30 days, with 90-day returns of +70.6%, +101.2%, -52.7%, and +63.6% respectively—3 of the 4 prior buys ultimately proved well-timed at the 90-day horizon. This latest acquisition occurs in the context of pronounced recent weakness and appears aligned with his historical pattern of accumulating during or after declines.

Director Eldred Kary bought 1,000 shares of GALT at $2.92 on 2025-07-21; director now holds 64,682 shares. Strong recent momentum (+113.4% over 90 days) vs unprofitable fundamentals.

Director Eldred Kary purchased 1,000 shares at $2.92, adding to a position that now totals 64,682 shares. His prior four transactions at Galectin Therapeutics show strong 90-day timing: three of the four measurable outcomes (2024-12-24, 2024-01-16, 2024-01-16) delivered positive 90-day returns of +101.2%, +119.0%, and +63.6% respectively, suggesting pattern recognition of entry points that preceded material gains. The current environment shows +113.4% upside over the past 90 days and +18.2% over the past 30 days, positioning this purchase well within a momentum phase. However, the company remains unprofitable with net income of $-9.6M, creating tension between insider accumulation and deteriorating fundamentals—a dynamic warranting deeper review of what operational or clinical developments may underpin the director's conviction at $2.92.

Director Eldred Kary buys 13,469 shares of GALT at $0.82 amid stock down 79.3% from 52-week high; cluster buy pattern with 2 other insiders in past 14 days.

Director Eldred Kary purchased 13,469 shares at $0.82 on 2024-12-24, increasing his holdings by 26.8% from 50,213 to 63,682 shares. The stock is trading at $0.87 currently, down 79.3% from its 52-week high of $4.20 and down 68.6% over the past 30 days, suggesting significant recent price deterioration. Notably, this buy is part of a cluster pattern—2 other insiders also purchased shares within the past 14 days—which may signal coordinated management response to depressed valuations. Kary's prior trades at GALT have shown a 100% 90-day win rate with outcomes ranging from +17.6% to +119.0%, though his most recent buy on 2024-10-23 at this same ticker is not yet measurable at 90 days. The company's trailing-twelve-month net income was negative at $-11,220,000, indicating the stock's decline reflects fundamental weakness rather than temporary market sentiment.

Director Eldred Kary buys 500 GALT shares at $2.60; stock down 38.6% from 52-week high; 3 prior buys at this ticker all well-timed at 90-day mark

Director Eldred Kary purchased 500 shares of Galectin Therapeutics at $2.60, increasing his holdings from 49,713 to 50,213 shares. The buy occurs while the stock trades at $2.58 (current price), down 38.6% from its 52-week high of $4.20, and the company reported a net loss of $-12.4M over its most recent full fiscal year. Notably, Kary's prior trading record at GALT shows a pattern of well-timed entry decisions: his three previous buys on 2024-01-16 and 2023-07-19 generated positive 90-day returns of +119.0%, +63.6%, and +17.6% respectively. However, the current depressed stock price and ongoing unprofitability merit scrutiny before inferring continued execution quality on this purchase; the 90-day outcome following this October 2024 transaction remains to be established.

Director Eldred Kary purchased 400 GALT shares at $2.39 on 2024-01-16 amid unprofitable operations; prior same-ticker buys generated +119.0% and +17.6% 90-day returns.

Eldred Kary, a director of Galectin Therapeutics, purchased 400 shares at $2.39, increasing his holdings to 49.7K shares. His prior two purchases at this ticker both delivered strong 90-day gains (+119.0% and +17.6%), suggesting he has demonstrated timing acuity with this specific stock. The company is unprofitable with a net income of $-11,489,000.00 over its most recent fiscal year, yet the stock has rebounded +10.7% over the past 30 days despite trading -38.3% below its 52-week high. The modest transaction size (400 shares, $956.00 total value) relative to his existing 49.3K share position represents a marginal 0.8% increase, limiting the weight one should place on conviction signaling alone. The alignment of this purchase with his track record of well-timed prior acquisitions at GALT warrants attention, but the absolute size and the company's ongoing losses temper the bullish implication.